SQZ Biotechnologies Current Ratio 2020-2023 | SQZ

SQZ Biotechnologies current ratio from 2020 to 2023. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
SQZ Biotechnologies Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2023-03-31 $0.04B $0.01B 3.50
2022-12-31 $0.07B $0.02B 3.12
2022-09-30 $0.09B $0.03B 3.46
2022-06-30 $0.11B $0.03B 3.87
2022-03-31 $0.13B $0.03B 4.34
2021-12-31 $0.15B $0.03B 4.53
2021-09-30 $0.17B $0.04B 4.25
2021-06-30 $0.19B $0.04B 4.32
2021-03-31 $0.21B $0.04B 4.98
2020-12-31 $0.18B $0.05B 3.91
2020-09-30 $0.12B $0.05B 2.35
2020-06-30 $0.00B 0.00
2020-03-31 $0.00B 0.00
2019-12-31 $0.00B 0.00
2019-09-30 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.017B $0.021B
SQZ Biotechnologies Company is a clinical-stage biotechnology company. It develops transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company's prime product candidate consist SQZ-PBMC-HPV which is in clinical stage. SQZ Biotechnologies Company is based In Watertown, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.076B 8.19
GSK (GSK) United Kingdom $70.106B 9.78
Bio-Rad Laboratories (BIO.B) United States $11.071B 29.60
QIAGEN (QGEN) Netherlands $10.491B 22.15
Ginkgo Bioworks Holdings (DNA) United States $3.170B 0.00
Arcus Biosciences (RCUS) United States $1.611B 0.00
Biohaven (BHVN) United States $1.059B 0.00
Emergent Biosolutions (EBS) United States $0.412B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.175B 0.00
Enzo Biochem (ENZ) United States $0.114B 0.00